StockWatch: Novartis Loses More than Market Value After Phase III Failure
Novartis (SIX Swiss: NOVN and NYSE: NVS) lost more than just the roughly $30 billion in market capitalization (share price times the number of outstanding shares) that dried up this past week when the...
Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program
Manus, The BioAlternatives Company®, and the University of Texas at Austin say they have completed a BioMADE-sponsored program to make industrial yeast fermentation more efficient and sustainable.
The project, carried out with Hal Alper, PhD,...
Data Integrity as the Foundation for AI
Artificial intelligence is advancing quickly into laboratory operations, which is why thinking about the quality and integrity of the supporting data early on is important. In regulated environments, that means understanding where the data...
The Emerging Power of Mass Spectrometry in Oncology
Globally, the incidence of newly diagnosed cancer cases is projected to increase over the next decade.1 Despite advancements in personalized medicine and therapeutic options, cancer diagnoses remain challenging.
Many patients are diagnosed at advanced stages...
Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial
Novartis shares fell the most in a single day since the COVID-19 pandemic after the pharma giant acknowledged that its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a pivotal Phase III trial assessing the antibody...
NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy
Switzerland-headquartered NewBiologix signed an agreement with Synastra Biotechnology to develop a stable producer cell line for Synastra’s investigational Duchenne muscular dystrophy (DMD) gene therapy program. Synastra, based in Turkey, was established through a collaboration...
Medicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases
Medicines Discovery Catapult (MDC) invested in two U.K. biotechs developing new approaches to treating diseases such as psoriasis. Parkinson’s Flip Therapeutics and Nascent Therapeutics will each receive £500,000 in funding made available by Innovate...
Micro-Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIs
Researchers headed by a team at the Centre for Kidney and Bladder Health, Division of Medicine, University College London, have used a novel human 3D micro-bladder model to demonstrate how phage therapy could help...
The Analytical Blueprint for Cell & Gene Therapy Success
Read NowCell and gene therapies have entered a new phase of maturity. Scientific innovation continues at an unprecedented pace, but so do the analytical and regulatory expectations that determine whether promising therapies ultimately reach...
Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory...
There is a particular kind of anxiety that settles into a biotech boardroom when the regulatory environment becomes difficult to read. It is not the anxiety of a bad clinical trial result that, at...
